Establishing risk of human experimentation with drugs: lessons from TGN1412

Central Committee on Research Involving Human Subjects, The Hague, Netherlands.
The Lancet (Impact Factor: 39.21). 11/2006; 368(9544):1387-91. DOI: 10.1016/S0140-6736(06)69562-7
Source: PubMed

ABSTRACT Particular care is necessary when a new drug is given to healthy volunteers without previous human testing. General principles for such research have been laid down in guidelines as early as 1983, and these were the basis for many current regulations. 2 Most drugs at that time were small molecules with fairly well characterised, classic, pharmacological mechanisms. Proposed primary objectives for studies in healthy people were therefore to show pharmacological action in man and the dose (or concentration) response curve. This approach was judged safe and was lent support by fi ndings of available surveys. 3,4

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Knockout, knock-in and conditional mutant gene-targeted mice are routinely used for disease modeling in the drug discovery process, but the human response is often difficult to predict from these models. It is believed that patient-derived induced pluripotent stem cells (iPSCs) could replace millions of animals currently sacrificed in preclinical testing and provide a route to new safer pharmaceutical products. In this review, we discuss the use of IPSCs in the drug discovery process. We highlight how they can be used to assess the toxicity and clinical efficacy of drug candidates before the latter are moved into costly and lengthy preclinical and clinical trials. Copyright © 2014 Elsevier Ltd. All rights reserved.
    Drug Discovery Today 11/2014; 20(1). DOI:10.1016/j.drudis.2014.10.011 · 5.96 Impact Factor
  • Journal of the American College of Cardiology 02/2015; 65(6):557-559. DOI:10.1016/j.jacc.2014.09.093 · 15.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of a new medicine is a risky and costly undertaking that requires careful planning. This planning is largely applied to the operational aspects of the development and less so to the scientific objectives and methodology. The drugs that will be developed in the future will increasingly affect pathophysiological pathways that have been largely unexplored. Such drug prototypes cannot be immediately introduced in large clinical trials. The effects of the drug on normal physiology, pathophysiology, and eventually the desired clinical effects will need to be evaluated in a structured approach, based on the definition of drug development as providing answers to important questions by appropriate clinical studies. This review describes the selection process for biomarkers that are fit-to-purpose for the stage of drug development in which they are used. This structured and practical approach is widely applicable and particularly useful for the early stages of innovative drug development. Expected final online publication date for the Annual Review of Pharmacology and Toxicology Volume 55 is January 06, 2015. Please see for revised estimates.
    Annual Review of Pharmacology 10/2014; 55(1). DOI:10.1146/annurev-pharmtox-011613-135918 · 18.52 Impact Factor

Full-text (2 Sources)

Available from
Dec 14, 2014